Read by QxMD icon Read

Hcc risk score

Alessandro Vitale, Quirino Lai, Fabio Farinati, Laura Bucci, Edoardo G Giannini, Lucia Napoli, Francesca Ciccarese, Gian Lodovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Rodolfo Sacco, Giuseppe Cabibbo, Roberto Virdone, Fabio Marra, Martina Felder, Filomena Morisco, Luisa Benvegnù, Antonio Gasbarrini, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Gabriele Missale, Alberto Masotto, Gerardo Nardone, Antonio Colecchia, Mauro Bernardi, Franco Trevisani, Timothy M Pawlik
BACKGROUND: Dichotomous models like Milan Criteria represent the routinely used tools for predicting the outcome of patients with hepatocellular carcinoma (HCC). However, a paradigm shift from a dichotomous to continuous prognostic stratification should represent a good strategy for improving the prediction process. Recently, the tumor burden score (TBS) has been proposed for selecting patients with colorectal liver metastases. To date, TBS has not been validated in a large HCC population...
January 19, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
Shin Hwang, Jae-Won Joh, Hee Jung Wang, Dong Goo Kim, Kyung Sik Kim, Kyung-Suk Suh, Seong Hoon Kim, Hee Chul Yu, Chol Kyoon Cho, Young-Joo Lee, Ki-Hun Kim, Jong Man Kim, Bong-Wan Kim, Sung-Gyu Lee
BACKGROUND: We developed a prognostic prediction model (PPM) using 4 factors for hepatic resection (HR) of large hepatic cellular carcinoma (HCC). Multiplication of α-fetoprotein (AFP), des-γ-carboxy prothrombin, and tumor volume (TV) (ADV score) is a surrogate marker for post-resection prognosis. This study intended to validate the predictive power of 4-factor PPM and to develop new ADV score-based PPM. METHODS: A total of 526 patients who underwent HR for solitary HCC ≥ 8 cm were selected from 9 Korean institutions between 2008 and 2014...
January 16, 2018: World Journal of Surgery
Carlo Spreafico, Carlo Sposito, Marta Vaiani, Tommaso Cascella, Sherrie Bhoori, Carlo Morosi, Rodolfo Lanocita, Raffaele Romito, Carlo Chiesa, Marco Maccauro, Alfonso Marchianò, Vincenzo Mazzaferro
BACKGROUND & AIMS: Yttrium-90 trans-arterial radioembolization (TARE) has shown promising efficacy in the treatment of patients with hepatocellular carcinoma (HCC) associated with tumoral portal vein thrombosis (PVTT). Aim of this study is to identify prognostic factors for survival in patients with HCC and PVTT undergoing TARE, and build a prognostic classification for these patients. METHODS: This is a single Center retrospective study conducted over 6 years (2010-2015), on consecutive patients undergoing TARE...
January 10, 2018: Journal of Hepatology
Ping-Hsien Chen, Wei-Yao Hsieh, Chien-Wei Su, Ming-Chih Hou, Yen-Po Wang, I-Fang Hsin, Tsung-Chieh Yang, Wei-Chih Liao, Han-Chieh Lin, Fa-Yauh Lee, Jaw-Ching Wu
BACKGROUND: s & Aims: There is no consensus for screening high-risk esophageal varices (HRV) in patients with hepatocellular carcinoma (HCC). Here, we aimed to investigate the prevalence and risk factors of HRV in HCC patients and to assess the combination of albumin-bilirubin grade and platelet count (ALBI-PLT score) for predicting compensated patients who do not need unnecessary endoscopic screening for HRV. METHODS: The ALBI-PLT score was calculated by adding ALBI grade and point of platelet count (1 point if platelet count >150,000 /mm3 and 2 points if ≦150,000 /mm3)...
January 6, 2018: Gastrointestinal Endoscopy
Giovanni Giretti, Louise Barbier, Petru Bucur, Frédéric Marques, Jean-Marc Perarnau, Martine Ferrandière, Anne-Charlotte Tellier, Vincent Kerouredan, Mario Altieri, Xavier Causse, Maryline Debette-Gratien, Christine Silvain, Ephrem Salamé
BACKGROUND: In France, liver grafts that have been refused by at least 5 teams are considered for rescue allocation, with the choice of the recipient being at the team's discretion. While this system permits the use of otherwise discarded grafts in a context of organ shortage, outcomes and potential benefits need to be assessed. METHODS: Between 2011 and 2015, outcomes of rescue allocation grafts (n=33) were compared to standard allocation grafts (n=321) at a single French center...
January 2, 2018: Transplantation
Noboru Shinkai, Masanori Nojima, Etsuko Iio, Kayoko Matsunami, Hidenori Toyoda, Shuko Murakami, Takako Inoue, Shintaro Ogawa, Takashi Kumada, Yasuhito Tanaka
BACKGROUND: Nucleot(s)ide analogues (NA) can reduce the risk of hepatocellular carcinoma (HCC), but not completely prevent its development. METHODS: Two hundred and thirty-four chronic hepatitis B patients virologically well controlled with entecavir or tenofovir disoproxil fumarate for more than 1 year were enrolled in this study. Over the median observation period of 51 (12-142) months, 24 of 234 patients developed HCC. We quantified HBV markers, alpha-fetoprotein (AFP) and Mac-2-binding protein glycosylation isomer (M2BPGi) at baseline and 48 weeks after therapy...
December 29, 2017: Journal of Gastroenterology
Suhg Namgoong, Joong-Gon Shin, Hyun Sub Cheong, Lyoung Hyo Kim, Ji On Kim, Jung Yeon Seo, Hyoung Doo Shin, Yoon Jun Kim
BACKGROUND & AIMS: Numerous single nucleotide polymorphisms (SNPs) associated with an increased risk of liver diseases, chronic hepatitis B (CHB) and CHB-related hepatocellular carcinoma (HCC), have been identified. In this study, we scrutinized the genetic effects of C2 variants, which were conflicting in previous results, on the risk of CHB in a Korean population. METHODS: We genotyped 22 common C2 genetic variants of 977 CHB cases including 302 CHB-related HCC cases and 785 population controls...
December 28, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
Maxime Ronot, Olivia Fouque, Maxime Esvan, Jérome Lebigot, Christophe Aubé, Valérie Vilgrain
BACKGROUND AND AIMS: To prospectively compare the diagnostic accuracy of the AASLD and LI-RADS v2014 criteria for the non-invasive diagnosis of small HCC, and to evaluate the diagnostic value of ancillary features used in the LI-RADS criteria. Between April 2009 and April 2012, patients with cirrhosis and one to three 10-30mm nodules were enrolled and underwent CT and MR imaging. The diagnostic accuracy of both the AASLD and the LI-RADS criteria were determined based on their sensitivity, specificity, positive (PPV) and negative predictive values (NPV)...
December 20, 2017: Journal of Hepatology
Y K Wang, X Y Bi, Z Y Li, H Zhao, J J Zhao, J G Zhou, Z Huang, Y F Zhang, M X Li, X Chen, X L Wu, R Mao, X H Hu, H J Hu, J M Liu, J Q Cai
Objective: To establish a new scoring system based on the clinicopathological features of hepatocellular carcinoma (HCC) to predict prognosis of patients who received hepatectomy. Methods: A total of 845 HCC patients who underwent hepatectomy from 1999 to 2010 at Cancer Hospital, Chinese Academy of Medical Sciences were retrospectively analyzed. 21 common clinical factors were selected in this analysis. Among these factors, the cut-off values of alpha-fetoprotein (AFP), alkaline phosphatase (ALP) and intraoperative blood loss were evaluated by using a receiver operating characteristic (ROC) curve analysis...
December 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
Gian Piero Guerrini, Domenico Pinelli, Elena Marini, Vittorio Corno, Michela Guizzetti, Marco Zambelli, Alessandro Aluffi, Lisa Lincini, Stefano Fagiuoli, Alessandro Lucianetti, Michele Colledan
CONTEXT: Liver transplantation (LT) is considered the ideal therapy for patients with hepatocellular carcinoma (HCC) having cirrhosis but the shortage of liver donors and the risk of dropout from the wait list due to tumor progression severely limit transplantation. A new prognostic score, the HCC-model for end-stage liver disease (HCC-MELD), was developed by combining α-fetoprotein (AFP), MELD, and tumor size, to improve risk stratification of dropout in patients with HCC. OBJECTIVES: In this study, we investigated the ability of the HCC-MELD score in predicting the posttransplant for patients fulfilling Milan criteria (MC)...
January 1, 2017: Progress in Transplantation
Franco Trevisani, Giovanni Brandi, Francesca Garuti, Maria Aurelia Barbera, Raffaella Tortora, Andrea Casadei Gardini, Alessandro Granito, Francesco Tovoli, Stefania De Lorenzo, Andrea Lorenzo Inghilesi, Francesco Giuseppe Foschi, Mauro Bernardi, Fabio Marra, Rodolfo Sacco, Giovan Giuseppe Di Costanzo
PURPOSE: Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study, as second-line therapy after sorafenib failure, in patients with hepatocellular carcinoma (HCC). METHODS: 117 patients undergoing MC were compared to 112 patients, eligible for this treatment, but undergoing best supportive care (BSC) after sorafenib discontinuation for toxicity or HCC progression. The two groups were compared for demographic and clinical features...
December 16, 2017: Journal of Cancer Research and Clinical Oncology
B G Tillman, J D Gorman, J M Hru, M H Lee, M C King, C B Sirlin, R M Marks
AIM: To evaluate the diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI (AMRI) in cirrhotic and chronic hepatitis B (CHB) patients for hepatocellular carcinoma (HCC) screening. MATERIALS AND METHODS: Seventy-nine consecutive patients at risk for HCC due to cirrhosis and/or CHB were included in this retrospective study. For each patient, the first gadoxetate disodium-enhanced MRI between 2008 through 2014 was analysed. Two independent readers read an anonymised abbreviated image set comprising axial T1-weighted (W) images with fat saturation in the hepatobiliary phase, 20 minutes or more after gadoxetate injection, and axial T2W single-shot fast spin echo images...
December 12, 2017: Clinical Radiology
Helen M Parsons, Quyen Chu, Jordan J Karlitz, Jennifer L Stevens, Linda C Harlan
Background: The adoption of sorafenib into oncology practice as a first-line systemic treatment for advanced hepatocellular carcinoma (HCC) is not well understood. We examined sorafenib use since Food and Drug Administration (FDA) approval in 2007 and associated survival for individuals diagnosed with advanced HCC, conducting a population-based evaluation of treatment patterns and outcomes for this newly approved drug in the US over time. Methods: We identified individuals diagnosed with Barcelona Clinic Liver Cancer Stage C from the 2007 and 2012 National Cancer Institute Patterns of Care study...
June 2017: Liver Cancer
Guillaume Conroy, Julia Salleron, Arthur Belle, Mouni Bensenane, Abdelbasset Nani, Ahmet Ayav, Didier Peiffert, Anthony Lopez, Cédric Baumann, Hélène Barraud, Jean-Pierre Bronowicki
Background and Aims: The multikinase inhibitor sorafenib is the only currently approved drug for the indication of advanced hepatocellular carcinoma (HCC). It provides a limited gain in survival time but is frequently associated with adverse events. We currently lack simple prognostic factors in sorafenib-treated HCC patients. Various inflammation-based scores (IBSs) have been evaluated as predictors of tumor recurrence and survival in various malignancies (including HCC). The objective of the present study was to determine the prognostic value of IBSs for overall survival (OS) in advanced HCC patients prior to the initiation of sorafenib therapy...
November 10, 2017: Oncotarget
Tyler A Sandow, Stephen E Arndt, Abeer A Albar, Daniel A DeVun, David S Kirsch, Juan M Gimenez, Humberto E Bohorquez, Patrick J Gilbert, Paul T Thevenot, Kelley G Nunez, Gretchen A Galliano, Ari J Cohen, Dennis Kay, Paul M Gulotta
Purpose To assess response to transcatheter arterial chemoembolization (TACE) based on immune markers and tumor biology in patients with hepatocellular carcinoma (HCC) who were bridged to liver transplantation, and to produce an optimized pretransplantation model for posttransplantation recurrence risk. Materials and Methods In this institutional review board-approved HIPAA-compliant retrospective analysis, 93 consecutive patients (73 male, 20 female; mean age, 59.6 years; age range, 23-72 years) underwent TACE with doxorubicin-eluting microspheres (DEB) (hereafter, DEB-TACE) and subsequently underwent transplantation over a 5-year period from July 7, 2011, to May 16, 2016...
December 4, 2017: Radiology
F Mettke, B Schlevogt, K Deterding, A Wranke, A Smith, K Port, M P Manns, A Vogel, M Cornberg, H Wedemeyer
BACKGROUND: Hepatitis C virus (HCV) clearance with IFN-based therapies reduces the incidence of hepatocellular carcinoma (HCC). There has been some debate if IFN-free therapy with direct-acting antivirals alters the risk for HCC. AIM: To investigate the HCC incidence in cirrhotic HCV patients who cleared HCV with direct-acting antivirals vs untreated controls. METHODS: We prospectively monitored 373 patients with chronic hepatitis C who received IFN-free therapies with direct-acting antiviral after January 2014...
December 4, 2017: Alimentary Pharmacology & Therapeutics
Irene Cacciola, Roberto Filomia, Angela Alibrandi, Maria Stella Franzè, Gaia Caccamo, Sergio Maimone, Carlo Saitta, Francesca Saffioti, Giovanni Squadrito, Giovanni Raimondo
BACKGROUND & AIMS: The outcome of compensated cirrhosis may vary considerably and cannot be predicted by routinely performed tests at present. Aim of this study was to evaluate possible predictors of clinical evolution in patients with Child-Pugh (C-P) class A cirrhosis due to untreatable causes by analysing clinical/biochemical/instrumental parameters evaluated at the time of diagnosis and during the subsequent long-lasting follow-up. METHODS: Two-hundred-seventy-two consecutive C-P class A cirrhotic patients (155 males; median age 63 years, range 34-81) were analysed...
December 1, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
Chien-Hung Chen, Chuan-Mo Lee, Hsueh-Chou Lai, Tsung-Hui Hu, Wen-Pang Su, Sheng-Nan Lu, Chia-Hsin Lin, Chao-Hung Hung, Jing-Houng Wang, Mei-Hsuan Lee, Cheng-Yuan Peng
Background: Until now, no risk score could predict hepatocellular carcinoma (HCC) in nucleos(t)ide analog (NA)-treated Asian patients. Methods: We enrolled 1325 NA-naïve chronic hepatitis B patients with entecavir monotherapy for >12 months, with 883 and 442 patients randomly assigned to the development and validation groups, respectively, in the risk model. Results: The cumulative probabilities of HCC were 2.4%, 4.1%, and 9.9% after 2, 3, and 5 years of treatment, respectively...
November 3, 2017: Oncotarget
Qing Pang, Lei Zhou, Kai Qu, Rui-Xia Cui, Hao Jin, Hui-Chun Liu
BACKGROUND AND OBJECTIVE: The objective of this study was to investigate the prognostic significance of several inflammation-based models in hepatitis B-associated hepatocellular carcinoma (HCC). PATIENTS AND METHODS: We retrospectively reviewed 470 cases of hepatitis B-associated HCC. Preoperative data were collected to calculate the inflammation-based markers, including systemic immune-inflammation index (neutrophil×platelets/lymphocyte), platelets-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio (NLR)...
January 2018: European Journal of Gastroenterology & Hepatology
Xiao Fei, Yun Ma, Xiaowei Liu, Zhixin Meng
SET and MYND domain-containing protein 3 (SMYD3) is a kind of histone lysine methyltransferase, responsible for transcriptional activation as a member of an RNA polymerase complex. The ectopic expression of SMYD3 is proved to promote the progress of many kinds of cancers. In hepatocellular carcinoma (HCC), SMYD3 was demonstrated to promote the proliferation and metastasis of HCC cell lines, but the clinical significance of SMYD3 has not been elucidated. In the present study, we detected the expression of SMYD3 in 100 HCC tissues with immunohistochemistry and divided these tissue specimens into high-expression group and low-expression group according to the immunohistochemical score of SMYD3...
2017: Tohoku Journal of Experimental Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"